Immunic, Inc (IMUX)

Trade IMUX now with
2/23/2023 6:50:02 AM Immunic FY Net Loss $120.4 Mln Or $3.78/shr Vs Net Loss $92.9 Mln Or $3.93/shr Prior Year
11/3/2022 6:32:26 AM Immunic Q3 Net Loss Widens To $21.2 Mln From $19.3 Mln Last Year
10/10/2022 10:26:51 AM Immunic Stock Surges 35%
10/10/2022 7:05:35 AM Immunic Unveils $60.0 Mln Oversubscribed Private Placement Equity Financing
9/21/2022 8:02:34 AM Wedbush Reiterates Immunic, Inc (IMUX) At Outperform With $11 Price Target
9/20/2022 6:31:20 AM Immunic Announces Positive Results From Single And Multiple Ascending Dose Parts Of Phase 1 Clinical Trial Of IMU-856
8/16/2022 6:39:01 AM Immunic Receives Notice Of Allowance For Composition-of-Matter Patent In The United States For IMU-856,
8/4/2022 6:47:10 AM Immunic, Inc. Q2 Net Loss Widens To $21.9 Mln From $17.9 Mln Last Year
7/6/2022 6:31:38 AM Immunic Appoints Maria Törnsén To Board, Effective July 5
6/15/2022 6:42:19 AM Immunic Publishes Data From Phase 2 EMPhASIS Trial Of Vidofludimus Calcium In Peer Reviewed Journal
6/2/2022 7:24:09 AM Immunic Says Phase 2 CALDOSE-1 Trial Fails To Meet Primary Endpoint In Ulcerative Colitis